U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
about
Discovery of Anticancer Agents of Diverse Natural OriginA human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinomaStructural Basis of Microtubule Destabilization by Potent Auristatin Anti-MitoticsDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia modelWhat's fueling the biotech engine-2011 to 2012.Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphomaMicrotubule inhibitor-based antibody-drug conjugates for cancer therapy.Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses.CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.90Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin's lymphomaResults of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancerCD30 targeting with brentuximab vedotin: a novel therapeutic approach to primary effusion lymphoma.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.CD30 as a therapeutic target for lymphoma.Industrial natural product chemistry for drug discovery and development.Emerging drugs for T-cell lymphoma.Monoclonal antibodies as therapeutics in human malignancies.Achieving incompatible transplantation through desensitization: current perspectives and future directions.Brentuximab vedotin for the treatment of Hodgkin's lymphoma.Antibody-Drug Conjugates: Design, Formulation and Physicochemical Stability.The new therapeutical scenario of Hodgkin lymphoma.Ibrutinib in B lymphoid malignancies.Bioanalytical approaches for characterizing catabolism of antibody-drug conjugates.Novel agents for the treatment of Hodgkin lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.Antibody-mediated delivery of therapeutics for cancer therapy.Merocyclophanes C and D from the Cultured Freshwater Cyanobacterium Nostoc sp. (UIC 10110).Increased Efficacy of Brentuximab Vedotin (SGN-35) in Combination with Cytokine-Induced Killer Cells in Lymphoma.KIR3DL2 (CD158k) is a potential therapeutic target in primary cutaneous anaplastic large-cell lymphoma.Advances in systemic delivery of anti-cancer agents for the treatment of metastatic cancer.Improving outcomes after allogeneic hematopoietic cell transplantation for Hodgkin lymphoma in the brentuximab vedotin eraPharmacokinetics, immunogenicity, and safety of weekly dosing of brentuximab vedotin in pediatric patients with Hodgkin lymphoma.FDA Approval Summary: Nivolumab for the Treatment of Relapsed or Progressive Classical Hodgkin Lymphoma.
P2860
Q28068341-85503352-26F3-4FB5-B3AC-D06386DE0BADQ28487973-061FFF99-8410-4F55-895A-955C71900842Q28553497-58C97456-59D3-4CE9-B550-9205992C603DQ30240160-A5291208-569A-4C80-9F15-311B66D6591EQ33875604-5A1615A6-5228-4781-9358-3E7C2372D955Q34316400-2645721F-620D-4393-A214-1E6F1A11F47BQ34325201-290FF4C2-D272-4164-B90F-F256CCEFC948Q34655256-5185D071-73D4-480E-AE91-009C6FCD27B1Q34718363-A6B2A5E6-A42B-4B27-95AA-389A23CC8AA8Q34802443-AE13F264-A54E-4014-B6B2-762A3C8E992DQ35168766-EE6389FA-7A29-49C8-BE05-2BF759E001D8Q35691210-6BF18842-27B2-44CA-8837-82F07327CF1CQ36207446-BCD04D35-79D0-42D9-A2B9-60CFEF35BE1EQ36264723-EB6C66FC-342E-46B3-8D7C-F70CA563D0FCQ36534677-1782184C-4E50-4DEC-85D2-9B2EBCA2881BQ36797398-0D897293-6B99-4CED-AA77-71550F9557F8Q36824455-35DC27FC-38E9-4644-B247-D12687D44E6FQ37098844-CB509AD9-A730-4D36-A6F8-E8D9DAD0AA1AQ37412853-93D7A25A-5C64-4E75-A4D5-45C8D9FBA80BQ38131563-6B114EB2-D7F9-4FD8-BF64-6034353F6759Q38138482-DCB9CEEB-4E9F-43A7-896C-7DE3D811EF85Q38154186-60CB6281-6563-4B59-8CD9-42CF1B39E41BQ38196943-C10C77DB-2C07-4651-8732-BB66A83D99FFQ38206275-062D1601-9D89-40DD-8CA4-7A40CF579B73Q38445336-A2AB65CE-AF9E-41C2-AC89-128149ED9F6AQ38476250-970CAC84-B697-499C-A2DB-DD4F9D9CBD31Q38489049-E4BC6EBB-E6B8-404E-9969-1217628A6005Q38513816-332C3E30-60AC-40B1-953C-EB3D7EEAB33AQ38545545-5F66CBEC-FC79-4EB3-BF47-E4607484FC2BQ38557519-2D1AD042-2C14-44D7-A99A-760A53DF7112Q38581830-641C840A-9E53-48A9-9C79-78449AE9AA6DQ38664909-58D0870A-0801-4053-8A5F-962A753F7686Q38665425-C7955623-C2CC-4B71-9F0F-1B1BC5A54BA8Q38714213-AFE98CBE-8208-4244-B930-E05B8394EB79Q38759986-EC13C966-F53D-49E7-A2CE-7AFC8F8C8CD5Q38781439-8AB42256-CDCC-4224-B326-16C60A111CF4Q38808823-93B2EA85-D12C-4502-AB44-6548E6CCD7D4Q38992200-4EFBF466-09F3-42CC-86B8-A1DD6339D349Q39193590-EA860F92-0FC5-4B99-8592-8CC701A6F9C6Q39259769-0A58A5F4-CC24-4D24-925C-A169DC5A16C7
P2860
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma.
description
2012 nî lūn-bûn
@nan
2012 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@ast
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@en
type
label
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@ast
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@en
prefLabel
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@ast
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@en
P2093
P1476
U.S. Food and Drug Administrat ...... naplastic large-cell lymphoma.
@en
P2093
Aakanksha Khandelwal
Ann Farrell
Bahru Habtemariam
Edvardas Kaminskas
Francisco Borrego
Haleh Saber
Janice Brown
Julie Bullock
Kallappa Koti
Karen McGinn
P304
P356
10.1158/1078-0432.CCR-12-1803
P407
P577
2012-09-07T00:00:00Z